These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 30383772)
1. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma. Tian Y; Zhao J; Ren P; Wang B; Zhao C; Shi C; Wei B; Ma J; Guo Y PLoS One; 2018; 13(11):e0201682. PubMed ID: 30383772 [TBL] [Abstract][Full Text] [Related]
2. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma]. Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951 [No Abstract] [Full Text] [Related]
3. [Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them]. Shi Y; Li P; Li B; Zhang F; Huang S; Shen S; Li X Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):299-305. PubMed ID: 31109439 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21. Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083 [TBL] [Abstract][Full Text] [Related]
5. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis. Sun Y; Wu M; Zhou M; Luo X; Guo Y; Bai H; Zhang Z; Tian W; Wang X; Bai Y; Zhu X; Pan H; Deng Y; Hu H; Xia J; Hao X; Han L; Wei M; Liu Y; Zeng M BMC Cancer; 2020 Jul; 20(1):646. PubMed ID: 32660443 [TBL] [Abstract][Full Text] [Related]
6. Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors. Chang HC; Chen YM; Tseng CC; Huang KT; Wang CC; Chen YC; Lai CH; Fang WF; Kao HC; Lin MC Tumour Biol; 2017 Mar; 39(3):1010428317695939. PubMed ID: 28351317 [TBL] [Abstract][Full Text] [Related]
7. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer. Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185 [TBL] [Abstract][Full Text] [Related]
8. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785 [TBL] [Abstract][Full Text] [Related]
9. Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs. Zhou F; Ma W; Li W; Ni H; Gao G; Chen X; Zhang J; Shi J BMC Cancer; 2018 Oct; 18(1):1033. PubMed ID: 30352571 [TBL] [Abstract][Full Text] [Related]
10. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer. Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127 [TBL] [Abstract][Full Text] [Related]
11. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer. Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384 [TBL] [Abstract][Full Text] [Related]
12. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study. Kim IA; Lee JS; Kim HJ; Kim WS; Lee KY BMC Cancer; 2018 Jul; 18(1):768. PubMed ID: 30055587 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745 [TBL] [Abstract][Full Text] [Related]
14. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs. Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428 [TBL] [Abstract][Full Text] [Related]
15. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation. Koo DH; Kim KP; Choi CM; Lee DH; Lee JC; Lee JS; Jang SJ; Kim SW Cancer Chemother Pharmacol; 2015 Jan; 75(1):197-206. PubMed ID: 25422153 [TBL] [Abstract][Full Text] [Related]
16. [Retrospective Study of Efficacy in BIM Gene Polymorphism on First-line EGFR-TKIs Treatment for Advanced Lung Adenocarcinoma]. Qian K; Zhang Y; Zhi X Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):543-548. PubMed ID: 28855035 [TBL] [Abstract][Full Text] [Related]
17. Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. Zhang B; Wang S; Qian J; Yang W; Qian F; Lu J; Zhang Y; Qiao R; Han B Cancer; 2018 Jun; 124(11):2399-2406. PubMed ID: 29543321 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases. Ke SB; Qiu H; Chen JM; Shi W; Chen YS Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070 [TBL] [Abstract][Full Text] [Related]
19. Survival outcome assessed according to tumor burden and progression patterns in patients with epidermal growth factor receptor mutant lung adenocarcinoma undergoing epidermal growth factor receptor tyrosine kinase inhibitor therapy. Cha YK; Lee HY; Ahn MJ; Choi YL; Lee JH; Park K; Lee KS Clin Lung Cancer; 2015 May; 16(3):228-36. PubMed ID: 25499173 [TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor Treatment and Salvage Chemotherapy in EGFR-Mutated Elderly Pulmonary Adenocarcinoma Patients. Tseng YH; Tseng YC; Lin YH; Lee YC; Perng RP; Whang-Peng J; Chen YM Oncologist; 2015 Jul; 20(7):758-66. PubMed ID: 26054633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]